FEATURE STORY
● The potential of gene therapy for mucopolysaccharidosis type I GENE THERAPY
● Repair of retinal degeneration following ex vivo Minicircle DNA gene therapy and transplantation of corrected photoreceptor progenitors RARE DISEASES
● Genetics and other omics in pediatric pulmonary arterial hypertension
● Natural history of adult patients with GM2 gangliosidosis
● Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine CLINICAL TRIALS – DATA
● Lentiviral gene therapy for X-linked chronic granulomatous disease INDUSTRIAL LANDSCAPE & AGREEMENTS
● Lonza supporting Rocket Pharma with clinical manufacturing of RP-L201 for the treatment of Leukocyte Adhesion Deficiency-I
● Bayer application for nifurtimox to treat pediatric patients with Chagas disease submitted for approval in US MISCELLANEOUS
● Towards European harmonisation of healthcare for patients with rare immune disorders
● Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions
FEATURE STORY
● The potential of gene therapy for mucopolysaccharidosis type I GENE THERAPY
● Repair of retinal degeneration following ex vivo Minicircle DNA gene therapy and transplantation of corrected photoreceptor progenitors RARE DISEASES
● Genetics and other omics in pediatric pulmonary arterial hypertension
● Natural history of adult patients with GM2 gangliosidosis
● Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine CLINICAL TRIALS – DATA
● Lentiviral gene therapy for X-linked chronic granulomatous disease INDUSTRIAL LANDSCAPE & AGREEMENTS
● Lonza supporting Rocket Pharma with clinical manufacturing of RP-L201 for the treatment of Leukocyte Adhesion Deficiency-I
● Bayer application for nifurtimox to treat pediatric patients with Chagas disease submitted for approval in US MISCELLANEOUS
● Towards European harmonisation of healthcare for patients with rare immune disorders
● Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions
FEATURE STORY
● The potential of gene therapy for mucopolysaccharidosis type I GENE THERAPY
● Repair of retinal degeneration following ex vivo Minicircle DNA gene therapy and transplantation of corrected photoreceptor progenitors RARE DISEASES
● Genetics and other omics in pediatric pulmonary arterial hypertension
● Natural history of adult patients with GM2 gangliosidosis
● Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine CLINICAL TRIALS – DATA
● Lentiviral gene therapy for X-linked chronic granulomatous disease INDUSTRIAL LANDSCAPE & AGREEMENTS
● Lonza supporting Rocket Pharma with clinical manufacturing of RP-L201 for the treatment of Leukocyte Adhesion Deficiency-I
● Bayer application for nifurtimox to treat pediatric patients with Chagas disease submitted for approval in US MISCELLANEOUS
● Towards European harmonisation of healthcare for patients with rare immune disorders
● Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions
COMMENTS ARE OFF THIS POST